Adage Capital Partners’s KalVista Pharmaceuticals KALV Stock Holding History

Adage Capital Partners’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-276,000	Closed	-$3.19M	–	899
2025 Q1	$3.19M	Sell	276,000 -24,000	-8%	-$245K	0.01%	737
2024 Q4	$2.54M	Sell	300,000 -1,119,792	-79%	-$11.6M	﹤0.01%	777
2024 Q3	$16.4M	Sell	1,419,792 -630,208	-31%	-$7.93M	0.03%	502
2024 Q2	$24.1M	Sell	2,050,000 -525,000	-20%	-$6.13M	0.04%	383
2024 Q1	$30.5M	Buy	2,575,000 +1,870,000	+265%	+$24.9M	0.06%	351
2023 Q4	$8.64M	Sell	705,000 -351,691	-33%	-$3.2M	0.02%	611
2023 Q3	$10.2M	Sell	1,056,691 -47,648	-4%	-$487K	0.02%	557
2023 Q2	$9.94M	Buy	1,104,339 +40,000	+4%	+$369K	0.02%	575
2023 Q1	$8.37M	Hold	1,064,339	–	–	0.02%	646
2022 Q4	$7.19M	Sell	1,064,339 -15,000	-1%	-$80.3K	0.02%	706
2022 Q3	$15.7M	Sell	1,079,339 -25,000	-2%	-$349K	0.04%	496
2022 Q2	$10.9M	Buy	1,104,339 +200,000	+22%	+$2.21M	0.02%	651
2022 Q1	$13.3M	Buy	904,339 +20,000	+2%	+$287K	0.03%	611
2021 Q4	$11.7M	Hold	884,339	–	–	0.02%	653
2021 Q3	$15.4M	Sell	884,339 -661	-0.1%	-$13.4K	0.03%	557
2021 Q2	$21.2M	Buy	885,000 +80,000	+10%	+$2.09M	0.04%	447
2021 Q1	$20.7M	Buy	805,000 +505,000	+168%	+$13.3M	0.04%	437
2020 Q4	$5.7M	Sell	300,000 -100,000	-25%	-$1.71M	0.01%	676
2020 Q3	$5.04M	Hold	400,000	–	–	0.01%	636
2020 Q2	$4.84M	Hold	400,000	–	–	0.01%	627
2020 Q1	$3.06M	Sell	400,000 -100,000	-20%	-$1.35M	0.01%	626
2019 Q4	$8.9M	Sell	500,000 -200,000	-29%	-$2.61M	0.02%	555
2019 Q3	$8.12M	Hold	700,000	–	–	0.02%	557
2019 Q2	$15.5M	Buy	700,000 +35,000	+5%	+$821K	0.04%	425
2019 Q1	$19M	Buy	665,000 +65,000	+11%	+$1.41M	0.05%	392
2018 Q4	$11.8M	Buy	600,000 +294,813	+97%	+$5.93M	0.03%	465
2018 Q3	$6.75M	Buy	+305,187	New	+$4.12M	0.02%	603

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Adage Capital Partners's KALV Position: Q2 2025 in Review

Adage Capital Partners sold out of KalVista Pharmaceuticals (KALV) in Q2 2025, closing a stake of 276,000 shares — an estimated $3.19M sold.

Adage Capital Partners first reported a position in KALV in Q3 2018 and held it in 27 quarters. The position peaked at $30.5M in Q1 2024. 139 funds tracked by Wall St. Rank hold KALV as of Q2 2025.

Adage Capital Partners reported no remaining KalVista Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Adage Capital Partners sold 276,000 KalVista Pharmaceuticals shares in Q2 2025, an estimated $3.19M.
Adage Capital Partners first reported a position in KalVista Pharmaceuticals in Q3 2018 and held it in 27 quarters.
Adage Capital Partners's KalVista Pharmaceuticals position peaked at $30.5M in Q1 2024.
139 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2025.

Based on Adage Capital Partners's 13F filing for Q2 2025, filed 14 Aug 2025.